Compare MFIC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | KURA |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 818.0M | 841.6M |
| IPO Year | N/A | 2015 |
| Metric | MFIC | KURA |
|---|---|---|
| Price | $9.49 | $10.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $11.25 | ★ $25.56 |
| AVG Volume (30 Days) | 549.5K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $9.47 | $5.45 |
| 52 Week High | $13.34 | $12.49 |
| Indicator | MFIC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 33.53 | 48.31 |
| Support Level | N/A | $8.62 |
| Resistance Level | $10.15 | $11.11 |
| Average True Range (ATR) | 0.23 | 0.53 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 3.09 | 7.14 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. The investment objective of the company is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.